EPCLUSA® (velpatasvir + sofosbuvir)

















HCV cure rates for Epclusa
Genotype No cirrhosis or Child-Pugh A Child-Pugh B/C
1 > 90% > 90%
2 > 90% > 90%
3 > 90% > 90%
4 > 90% > 90%
5 > 90% N/A
6 > 90% N/A



Reference [2]
Side effect Epclusa® for 12 weeks
(N=624)
Placebo for 12 weeks
(N=116)
Headache 29% 28%
Fatigue 20% 20%
Nasopharyngitis 13% 10%
Nausea 12% 11%
Insomnia 8% 9%
Diarrhea 8% 7%
Asthenia 7% 8%
Arthralgia 6% 8%
Cough 6% 3%
Lipase elevations
> 3 X ULN
3% 1%
Rash 2% 1%
Depression 1% 0%
CK elevations
> 10 X ULN
1% 0%


















  • Previous treatment with regimens containing PegIFN/RBV with or without an HCV NS3/4A PI (boceprevir, simeprevir, or telaprevir)
Epclusa treatment regimens for GT 1, 2, 3, 4, 5, and 6
Patient population Treatment
Treatment-naïve and treatment-experienced with no cirrhosis or Child-Pugh A Epclusa for 12 weeks
Treatment-naïve and treatment-experienced with Child-Pugh B or C Epclusa + weight-based ribavirin for 12 weeks
Liver transplant recipients who are treatment-naïve or treatment-experienced with no cirrhosis or Child-Pugh A Epclusa for 12 weeks